IHLAL

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸƒ Esg

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

40
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Incannex Healthcare Limited - Option Expiring 22-Apr-2022 Deferred

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

empty share chartempty share line

Performance graph isn't available yet for this share

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in IHLAL

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in IHLAL

N/A
IHLAL investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in IHLAL also invest in...

Incannex Healthcare Limited

IHL

Incannex Healthcare Ltd. is a clinical stage pharmaceutical development company, which engages in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-05-23. The firm is engaged in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The firm targets five indications: obstructive sleep apnea (OSA), traumatic brain injury and concussion (TBI), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and inflammatory lung conditions. Its drug candidates include IHL-42X, IHL-216A, Psilocybin-assisted psychotherapy for general anxiety disorder (Psi-GAD) and IHL-675A. Its IHL-42X is a cannabinoid combination product for treatment of OSA. Its IHL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. IHL-216A is a cannabinoid combination product for the treatment of TBI. The company is investigating the use of psilocybin-assisted psychotherapy to treat GAD.

πŸ™Œ Performance (5Yr p.a)

21.00%

πŸ“Š Share price

$0.04 AUD

NULL STOCK

Find Out More

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

4.35%

πŸ“Š Share price

$104.33 AUD

⛳️ DIVERSIFIED

🧱 MATERIALS

πŸ’Έ FINANCIALS

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

πŸ™Œ Performance (5Yr p.a)

12.66%

πŸ“Š Share price

$82.30 AUD

πŸ€– TECHNOLOGY

🏭 INDUSTRIALS

πŸ“ˆ HIGH PRICE GROWTH

🌏 GLOBAL

πŸ›οΈ CONSUMER

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6041.2m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

πŸ™Œ Performance (5Yr p.a)

4.86%

πŸ“Š Share price

$140.68 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

πŸ’Έ FINANCIALS

⛳️ DIVERSIFIED